Roivant CEO hints at more deals shaping up as key Immunovant data loom
Roivant Sciences has more potential asset deals in the works — after setting up two Vants around Pfizer assets in the past two years — and hopes to be talking about them in 2024, CEO Matt Gline told analysts on a quarterly earnings call on Monday morning.
Before that, key data from its family of Vants, including clinical trial readouts from two anti-FcRn assets at the publicly-traded Immunovant, are on tap. The data could dictate the direction Roivant takes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.